Literature DB >> 26026863

Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy.

Raymond H Chan1, Barry J Maron2, Iacopo Olivotto3, Gabriele E Assenza4, Tammy S Haas2, John R Lesser2, Christiane Gruner5, Andrew M Crean6, Harry Rakowski6, Ethan Rowin7, James Udelson7, Massimo Lombardi8, Benedetta Tomberli3, Paolo Spirito9, Francesco Formisano9, Martina P Marra10, Elena Biagini11, Camillo Autore4, Warren J Manning12, Evan Appelbaum12, William C Roberts13, Cristina Basso10, Martin S Maron7.   

Abstract

Cardiovascular magnetic resonance (CMR) with extensive late gadolinium enhancement (LGE) is a novel marker for increased risk for sudden death (SD) in patients with hypertrophic cardiomyopathy (HC). Small focal areas of LGE confined to the region of right ventricular (RV) insertion to ventricular septum (VS) have emerged as a frequent and highly visible CMR imaging pattern of uncertain significance. The aim of this study was to evaluate the prognostic significance of LGE confined to the RV insertion area in patients with HC. CMR was performed in 1,293 consecutive patients with HC from 7 HC centers, followed for 3.4 ± 1.7 years. Of 1,293 patients (47 ± 14 years), 134 (10%) had LGE present only in the anterior and/or inferior areas of the RV insertion to VS, occupying 3.7 ± 2.9% of left ventricular myocardium. Neither the presence nor extent of LGE in these isolated areas was a predictor of adverse HC-related risk, including SD (adjusted hazard ratio 0.82, 95% confidence interval 0.45 to 1.50, p = 0.53; adjusted hazard ratio 1.16/10% increase in LGE, 95% confidence interval 0.29 to 4.65, p = 0.83, respectively). Histopathology in 20 HC hearts show the insertion areas of RV attachment to be composed of a greatly expanded extracellular space characterized predominantly by interstitial-type fibrosis and interspersed disorganized myocyte patterns and architecture. In conclusion, LGE confined to the insertion areas of RV to VS was associated with low risk of adverse events (including SD). Gadolinium pooling in this region of the left ventricle does not reflect myocyte death and repair with replacement fibrosis or scarring.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26026863     DOI: 10.1016/j.amjcard.2015.04.060

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

1.  Clinical importance of late gadolinium enhancement at right ventricular insertion points in otherwise normal hearts.

Authors:  Chrysanthos Grigoratos; Adriana Pantano; Maria Meschisi; Raffaella Gaeta; Lamia Ait-Ali; Andrea Barison; Giancarlo Todiere; Pierluigi Festa; Gianfranco Sinagra; Giovanni Donato Aquaro
Journal:  Int J Cardiovasc Imaging       Date:  2020-02-06       Impact factor: 2.357

Review 2.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 3.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

4.  Lifelong Physical Activity Regardless of Dose Is Not Associated With Myocardial Fibrosis.

Authors:  Shuaib M Abdullah; Kyler W Barkley; Paul S Bhella; Jeffrey L Hastings; Susan Matulevicius; Naoki Fujimoto; Shigeki Shibata; Graeme Carrick-Ranson; M Dean Palmer; Nainesh Gandhi; Laura F DeFina; Benjamin D Levine
Journal:  Circ Cardiovasc Imaging       Date:  2016-11       Impact factor: 7.792

Review 5.  Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging.

Authors:  Takeshi Kitai; Andrew Xanthopoulos; Shoko Nakagawa; Natsuko Ishii; Masashi Amano; Filippos Triposkiadis; Chisato Izumi
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-25

6.  Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy.

Authors:  Eiryu Sai; Kazunori Shimada; Takayuki Yokoyama; Makoto Hiki; Shuji Sato; Nozomi Hamasaki; Masaki Maruyama; Ryoko Morimoto; Tetsuro Miyazaki; Shinichiro Fujimoto; Yoshifumi Tamura; Shigeki Aoki; Hirotaka Watada; Ryuzo Kawamori; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2016-05-03       Impact factor: 2.037

7.  Nonischemic Left Ventricular Scar as a Substrate of Life-Threatening Ventricular Arrhythmias and Sudden Cardiac Death in Competitive Athletes.

Authors:  Alessandro Zorzi; Martina Perazzolo Marra; Ilaria Rigato; Manuel De Lazzari; Angela Susana; Alice Niero; Kalliopi Pilichou; Federico Migliore; Stefania Rizzo; Benedetta Giorgi; Giorgio De Conti; Patrizio Sarto; Luis Serratosa; Giampiero Patrizi; Elia De Maria; Antonio Pelliccia; Cristina Basso; Maurizio Schiavon; Barbara Bauce; Sabino Iliceto; Gaetano Thiene; Domenico Corrado
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-07

Review 8.  Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy.

Authors:  Juan Carlos Brenes; Adelina Doltra; Susanna Prat
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

9.  Role of cardiovascular magnetic resonance in suspected cardiac amyloidosis: late gadolinium enhancement pattern as mortality predictor.

Authors:  M Baroni; S Nava; G Quattrocchi; A Milazzo; C Giannattasio; A Roghi; P Pedrotti
Journal:  Neth Heart J       Date:  2018-01       Impact factor: 2.380

10.  Prognostic implications of late gadolinium enhancement at the right ventricular insertion point in patients with non-ischemic dilated cardiomyopathy: A multicenter retrospective cohort study.

Authors:  Jeong-Eun Yi; Junbeom Park; Hye-Jeong Lee; Dong Geum Shin; Yookyung Kim; Minsuk Kim; Kihwan Kwon; Wook Bum Pyun; Young Jin Kim; Boyoung Joung
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.